Mereo BioPharma Group PLCNASDAQ:MREO
- LAST PRICE4.8300
- TODAY'S CHANGE (%)0.3200 (7.0953%)
- Bid / Lots4.8500/ 1
- Ask / Lots4.9000/ 5
- Open / Previous Close4.6200 / 4.5100
- Day Range
- 52 Week Range
- Volume1,896,113
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
Aug 13, 2024
DJ Mereo BioPharma Group Price Target Maintained With a $7.00/Share by Needham, from 2:06PM ET on Tuesday Aug 13, 2024 by Dow Jones
2:06PM ET on Tuesday Aug 13, 2024 by Dow JonesPress Release: Mereo BioPharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update, from 8:00AM ET on Tuesday Aug 13, 2024 by Dow Jones
8:00AM ET on Tuesday Aug 13, 2024 by Dow JonesMereo BioPharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update, from 8:00AM ET on Tuesday Aug 13, 2024 by Dow Jones
8:00AM ET on Tuesday Aug 13, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Mereo BioPharma Group PLC | 743.1M | -14.7x | --- |
Tarsus Pharmaceuticals Inc | 971.2M | -5.8x | --- |
Immunome Inc | 927.8M | -2.7x | --- |
Relay Therapeutics Inc | 964.0M | -2.9x | --- |
Viridian Therapeutics Inc | 961.5M | -3.5x | --- |
89Bio Inc | 937.8M | -4.5x | --- |
Company Information
Mereo BioPharma Group plc is a biopharmaceutical company. It is focused on the development of therapeutics for rare diseases. It has developed a portfolio of clinical-stage product candidates. The Company has two rare disease product candidates: setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat for the treatment of severe alpha-1-antitrypsin deficiency-associated lung disease (AATD-LD) and bronchiolitis obliterans syndrome (BOS). It also has two oncology product candidates in clinical development. It also includes Etigilimab, an antibody against TIGIT (T-cell immunoreceptor with Ig and ITIM domains). Its non-core partnered programme, Navicixizumab, is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Its non-core programs available for partnership include Acumapimod and Leflutrozole. Acumapimod is a p38 MAP kinase inhibitor therapy for treatment during severe acute exacerbations of COPD (AECOPD).
Contact Information
- Headquarters
- One Cavendish Place, Fourth FloorLONDON, United Kingdom W1G0QF
- Phone
- ---
- Fax
- ---
Executives
- Non-Executive Independent Chairman of the Board
- Michael Wyzga
- Chief Executive Officer, Director
- Denise Scots-Knight
- Chief Financial Officer
- Christine Fox
- Senior Vice President - Clinical Development
- Suba Krishnan
- Senior Vice President - Therapeutic Head
- Jackie Parkin
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $743.1M |
|---|---|
Revenue (TTM) | $10.5M |
Shares Outstanding | 153.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.97 |
EPS | $-0.33 |
Book Value | $0.46 |
P/E Ratio | -14.7x |
Price/Sales (TTM) | 71.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -416.58% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
